Navigation Links
Chilean President's Cousin Successfully Tests Allergy 'Knockout' Technique on Mice

A doctoral student at the Hebrew University of Jerusalem School of Pharmacy, who is the first cousin of Chilean President Michelle Bachelet, has been conferred a prestigious research prize for developing a new approach that may help eliminate allergies like the common cold and asthma.

Chilean-born Ido Bachelet has been honoured with the Barenholz Prize, which is named for the donor of the prize money and noted researcher Prof. Yehezkel Barenholz of the Hebrew University-Hadassah Medical School, in recognition of his contribution in the development of the "knockout technique" in special "antibody nose drops" against allergies that has been tested successfully on lab mice.

Bachelet shared the award with another researcher during the Hebrew University Borad of Governors 70th meeting in Jerusalem recently. The award is given for "creativity and originality in applied research".

The Ph.D student, who is working under the supervision of Prof. Francesca Levi-Schaffer, focused his research on mechanisms that regulate the function of mast cells, the "villains" in triggering allergic reactions.

Acute symptoms like stuffy nose, rash and airway constriction, and lethal shock known from food or venom allergies occur when, as a result of exposure to allergens, mast cells react violently and release an enormous array of pro-inflammatory substances, of which histamine is a well-known example. They later on attract inflammatory cells that will maintain the response, which often persists as a chronic disease.

Bachelet's study has led to the identification of a receptor protein on mast cells, termed CD300a, which has a prominent negative effect on mast cell activity, virtually shutting down the cell from unleashing allergic responses.

The identified protein receptor is widely found throughout the immune system and, just like steroids, targeting it could result in undesired, overall immune suppressi on with serious consequences.

With a view to overcome this problem, Bachelet and his research colleague Ariel Munitz have designed a small, synthetic, antibody fragment that has the unusual ability of recognizing two targets simultaneously-the receptor CD300a and a mast cell-specific marker. This makes the antibody targets CD300a only on the surface of mast cells, avoiding suppression of other immune cells.

During the study, this antibody potently eliminated four different types of allergic diseases in mice. The researchers also noted that upon administration of the antibody in nose drops, mice suffering from sever chronic asthma completely reverted to normal in less than two months.

Termed RECEPTRA, the pioneering project presents a novel therapeutic strategy for acute and chronic allergic diseases, and is currently being licensed through Yissum, the Hebrew University's technology transfer company, to pharmaceutical companies for further development and eventual clinical trials.

Bachelet predicts that with further development, his technology may become the first line of allergy therapy in the near future.


'"/>




Related medicine news :

1. Former Chilean Dictator Hospitalised After Heart Attack
2. Former Chilean Dictator Recovering
3. Chicken Dishes Were Off The Menu At Pakistan Presidents House
4. Reserved category doctors seek Presidents intervention
5. US Senate Approves Embryo-research Plan Despite Presidents Refusal
6. Cipro Has Cheaper Cousins to Treat Anthrax
7. Fruitfly My Distant Cousin
8. Cousins Recovering from His Substance Abuse Problem
9. Cousins Recovering from His Substance Abuse Problem
10. French Doctors Successfully Separate Twins Joined At Spine
11. Alzheimer’s disease trial With EVT 101 For Successfully Complete
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2016)... ... February 08, 2016 , ... ... states in the U.S. require dental technicians to be certified or obtain continuing ... industry, NADL created the “What’s In Your Mouth?” campaign to inform dentists and ...
(Date:2/7/2016)... ... February 07, 2016 , ... Women's Excellence staff, in all four locations, wore ... Wear Red Day is the first Friday each February and a day to bring ... in 3 deaths among women each year – more than all cancers combined. Go ...
(Date:2/7/2016)... ... 2016 , ... Dr. Todd Hobgood , certificated in ... surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, Kybella® ... for reduction of fat below the chin (aka the “double chin”). Medication side ...
(Date:2/6/2016)... ... ... US Sports Camps is proud to sponsor the Bay Area Disc Association's ... leaders, ultimate organizations, and coaches from around the US. The theme for this year’s ... of Youth and Education, describes this year YUCC as “an important conversation we must ...
(Date:2/6/2016)... , ... February 06, 2016 , ... Shark Finds ... announce the launch of a new DRTV campaign with Belly Bands. , Having a ... everything from sprays to puppy pads and find nothing works, get Belly Bands, ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016   GS1 US will ... guide them through GS1 Standards implementation to address the ... Unique Device Identification (UDI) rule. Scott ... Beth Gibson , senior director industry development, medical devices, ... director, GS1 US --> Scott ...
(Date:2/8/2016)... Feb. 8, 2016 Nueterra, the ... specialized in the development of equity partnerships ... it has divided its interests between two ... Capital will continue the founding company,s private ... operate a national system of integrated provider ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016   ... November Research Group (NRG),s pharmacovigilance technology services ... system-related consulting services and an Oracle Argus Specialized ... services to Life Sciences companies. ... and expands HighPoint,s life sciences capabilities and provides ...
Breaking Medicine Technology: